Annual Total Expenses
$554.56 M
+$32.58 M+6.24%
December 31, 2024
Summary
- As of February 26, 2025, TVTX annual total expenses is $554.56 million, with the most recent change of +$32.58 million (+6.24%) on December 31, 2024.
- During the last 3 years, TVTX annual total expenses has risen by +$223.30 million (+67.41%).
- TVTX annual total expenses is now at all-time high.
Performance
TVTX Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Expenses
$134.12 M
+$15.20 M+12.78%
December 1, 2024
Summary
- As of February 26, 2025, TVTX quarterly total expenses is $134.12 million, with the most recent change of +$15.20 million (+12.78%) on December 1, 2024.
- Over the past year, TVTX quarterly total expenses has increased by +$6.22 million (+4.87%).
- TVTX quarterly total expenses is now -25.63% below its all-time high of $180.35 million, reached on March 31, 2024.
Performance
TVTX Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Expenses Formula
Total Expenses = Cost of Goods Sold + Operating Expenses + Non Operating Expenses
TVTX Total Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +6.2% | +4.9% |
| 3 y3 years | +67.4% | +4.9% |
| 5 y5 years | +101.5% | +4.9% |
TVTX Total Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +67.4% | -25.6% | +90.5% |
| 5 y | 5-year | at high | +102.6% | -25.6% | +107.1% |
| alltime | all time | at high | >+9999.0% | -25.6% | >+9999.0% |
Travere Therapeutics Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $554.56 M(+6.2%) | - |
| Dec 2024 | - | $134.12 M(+12.8%) |
| Sep 2024 | - | $118.92 M(-1.9%) |
| Jun 2024 | - | $121.17 M(-32.8%) |
| Mar 2024 | - | $180.35 M(+41.0%) |
| Dec 2023 | $521.98 M(+21.6%) | $127.90 M(-1.4%) |
| Sep 2023 | - | $129.68 M(-4.8%) |
| Jun 2023 | - | $136.15 M(+6.2%) |
| Mar 2023 | - | $128.26 M(+10.5%) |
| Dec 2022 | $429.27 M(+29.6%) | $116.04 M(+4.8%) |
| Sep 2022 | - | $110.68 M(-3.5%) |
| Jun 2022 | - | $114.71 M(+8.7%) |
| Mar 2022 | - | $105.54 M(+49.9%) |
| Dec 2021 | $331.26 M(+21.0%) | $70.41 M(-18.2%) |
| Sep 2021 | - | $86.06 M(-2.7%) |
| Jun 2021 | - | $88.42 M(+2.4%) |
| Mar 2021 | - | $86.37 M(+13.4%) |
| Dec 2020 | $273.70 M(-0.5%) | $76.20 M(+16.3%) |
| Sep 2020 | - | $65.49 M(-2.6%) |
| Jun 2020 | - | $67.25 M(+3.9%) |
| Mar 2020 | - | $64.76 M(-1.3%) |
| Dec 2019 | $275.15 M(+18.1%) | $65.62 M(+2.8%) |
| Sep 2019 | - | $63.81 M(-18.1%) |
| Jun 2019 | - | $77.88 M(+16.0%) |
| Mar 2019 | - | $67.13 M(+12.3%) |
| Dec 2018 | $232.94 M(+25.4%) | $59.80 M(+0.2%) |
| Sep 2018 | - | $59.69 M(-1.7%) |
| Jun 2018 | - | $60.74 M(+15.2%) |
| Mar 2018 | - | $52.72 M(+9.8%) |
| Dec 2017 | $185.73 M | $48.02 M(+5.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2017 | - | $45.39 M(-7.6%) |
| Jun 2017 | - | $49.11 M(+9.9%) |
| Mar 2017 | - | $44.68 M(-5.9%) |
| Dec 2016 | $172.53 M(+30.6%) | $47.49 M(-2.4%) |
| Sep 2016 | - | $48.66 M(+16.1%) |
| Jun 2016 | - | $41.90 M(+21.3%) |
| Mar 2016 | - | $34.55 M(-11.2%) |
| Dec 2015 | $132.15 M(+22.4%) | $38.90 M(+5.5%) |
| Sep 2015 | - | $36.88 M(+19.4%) |
| Jun 2015 | - | $30.89 M(+21.3%) |
| Mar 2015 | - | $25.48 M(-22.3%) |
| Dec 2014 | $108.01 M(+336.0%) | $32.78 M(+8.5%) |
| Sep 2014 | - | $30.22 M(+31.8%) |
| Jun 2014 | - | $22.92 M(+3.8%) |
| Mar 2014 | - | $22.09 M(+80.1%) |
| Dec 2013 | $24.77 M(-18.1%) | $12.27 M(+138.0%) |
| Sep 2013 | - | $5.15 M(+1.1%) |
| Jun 2013 | - | $5.10 M(+170.5%) |
| Mar 2013 | - | $1.89 M(>+9900.0%) |
| Dec 2012 | $30.26 M(>+9900.0%) | - |
| Nov 2012 | - | $3200.00(+6.7%) |
| Aug 2012 | - | $3000.00(0.0%) |
| May 2012 | - | $3000.00(-21.1%) |
| Feb 2012 | - | $3800.00(+26.7%) |
| Feb 2012 | $12.80 K(+0.8%) | - |
| Nov 2011 | - | $3000.00(0.0%) |
| Aug 2011 | - | $3000.00(0.0%) |
| May 2011 | - | $3000.00(-16.7%) |
| Feb 2011 | $12.70 K | $3600.00(+16.1%) |
| Nov 2010 | - | $3100.00 |
FAQ
- What is Travere Therapeutics annual total expenses?
- What is the all time high annual total expenses for Travere Therapeutics?
- What is Travere Therapeutics annual total expenses year-on-year change?
- What is Travere Therapeutics quarterly total expenses?
- What is the all time high quarterly total expenses for Travere Therapeutics?
- What is Travere Therapeutics quarterly total expenses year-on-year change?
What is Travere Therapeutics annual total expenses?
The current annual total expenses of TVTX is $554.56 M
What is the all time high annual total expenses for Travere Therapeutics?
Travere Therapeutics all-time high annual total expenses is $554.56 M
What is Travere Therapeutics annual total expenses year-on-year change?
Over the past year, TVTX annual total expenses has changed by +$32.58 M (+6.24%)
What is Travere Therapeutics quarterly total expenses?
The current quarterly total expenses of TVTX is $134.12 M
What is the all time high quarterly total expenses for Travere Therapeutics?
Travere Therapeutics all-time high quarterly total expenses is $180.35 M
What is Travere Therapeutics quarterly total expenses year-on-year change?
Over the past year, TVTX quarterly total expenses has changed by +$6.22 M (+4.87%)